A diagnostics company can spend decades building deep, well-earned credibility with hospital laboratories. Then a difficult seasonal comparison in one of its largest product lines can make a broader truth visible: some of its most stable growth potential may sit with buyers the hospital-facing team rarely addresses directly.
These buyers may work in food or pharmaceutical manufacturing. Their concerns are not infectious disease or clinical workflows, but contamination, spoilage, product quality and production continuity.
Reaching them requires more than repurposing clinical content. It calls for a dedicated go-to-market strategy for industrial diagnostics.
Same science, a different industrial buying context
A hospital lab director and a food safety quality manager both care about detecting the presence of something harmful. Almost everything else about how they buy, what convinces them and who they trust is different.
They operate in different environments, evaluate different risks and involve different stakeholders in the buying process. Content built for one audience will therefore rarely work equally well for the other, even when the underlying microbiology is identical.
Why industrial diagnostics markets remain underdeveloped
It is natural for a company’s strongest commercial and marketing capabilities to keep absorbing most of the attention.
When clinical diagnostics represents the larger and more familiar part of the business, marketing materials, sales conversations and proof points are often built primarily around hospital and laboratory audiences.
The industrial or manufacturing side can consequently remain a smaller, less-resourced afterthought, even when it offers strategically valuable and potentially less seasonal growth.
The issue is not necessarily the strength of the product portfolio. It is that the industrial offering is still being explained through a clinical commercial lens.
What an industrial diagnostics go-to-market strategy includes
The solution is not simply to create more hospital content or make existing materials slightly broader. A dedicated industrial diagnostics go-to-market strategy starts with the industrial buyer and defines:
- the most relevant market segments and applications
- the needs, risks and decision criteria of each buyer
- a clear value proposition for the industrial environment
- relevant scientific and commercial proof points
- the right content, channels and customer journeys
- sales tools that support credible industrial conversations
This does not require abandoning the scientific credibility the company has built over decades. It means translating that credibility into a commercial approach designed for a different market.
The strategic question diagnostics companies should ask
The question is not only: “How do we grow the hospital business further?”
It is also: “What would it take to give our industrial buyers the same quality of go-to-market support that our hospital buyers have received for decades?”
When the market, buyer and buying process are different, the go-to-market approach should reflect that difference.
How Living Stone supports go-to-market strategy
This is where Living Stone’s Go-to-Market work comes in. We help companies build dedicated market-entry approach for underserved buyer segments within an already strong portfolio.
By connecting market discovery, positioning, messaging, content, channel strategy and sales enablement, we help companies turn a promising market opportunity into a clear and commercially actionable approach.
Is an industrial buyer segment still being treated as an extension of your clinical market?
Explore how Living Stone approaches Go-to-Market.
